Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | PDE6C | P51160 | 2/20 | 0.75 |
| ▸ | PDE1A | P54750 | 2/20 | 0.75 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.75 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.68 |
| ▸ | PDE2A | O00408 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.67 |
| ▸ | PDE6D | O43924 | 1/20 | 0.67 |
| ▸ | PDE8A | O60658 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7958884 | 0.93 | PDE5A (0.66) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL18715171 | 0.88 | PDE5A (0.75) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL7950435 | 0.88 | KMT2A (0.77) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL29416347 | 0.88 | PDE5A (0.75) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL17390249 | 0.88 | PDE5A (0.75) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL15996180 | 0.87 | PDE5A (0.73) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL14836876 | 0.87 | PDE5A (0.73) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL7961638 | 0.86 | PDE5A (0.83) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL1202 | 0.86 | PDE5A (1.00) | PDE5AKMT2APDE6CPDE1APDE1B | |
| SCHEMBL31174349 | 0.86 | PDE5A (1.00) | PDE5AKMT2APDE6CPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969744-B2 | Compounds for use in cognition improvement | FUNDACIÓN LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-05-15 | — | — | US | disclosed |
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-03 | — | — | US | disclosed |
| EP-2961741-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUND PARA LA INVESTIG MEDICA APLICADA (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | CHAT, NLN, GRIN2C | PDE5A 1677/4885KMT2A 1826/4885PDE6C 2338/4885 |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | PDE1A, HDAC1, HDAC2 | PDE5A 24/4885KMT2A 98/4885PDE6C 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.